The above table from the paper in the Apr 2010 issue of Circulation (#msg-48705801) shows the prespecified non-inferiority analysis.
The criterion for a finding of non-inferiority was that the upper bound of the 90% confidence interval on the primary endpoint delta of M118 relative to unfractionated heparin (UFH) was less than 0.08 (i.e. 8.0 percentage points). This criterion was met by each individual M118 arm and by the composite of the three M118 arms.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.